384 Comparative Efficacy of Perioperative Blood Conservation Agents in Pediatric Cranial Vault Remodeling: A Systematic Review and Network Meta-analysis

View at publisher Summarise with VIRAT
Authors: Christopher Padilla, Michael Farid, Parker D. Smith, Kwadwo Darko, Sean O’Leary, Bennett Reuben Levy, Umaru Barrie, Hammad A. Khan, Salah G. Aoun, David H. Harter
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Red blood cell (RBC) transfusions are commonly required in pediatric cranial vault remodeling (CVR), however, they carry risks and potential complications. METHODS: A systematic review was conducted using PubMed/MEDLINE, SCOPUS, Embase, Web of Sciences and Google Scholar according to PRISMA guidelines to assess articles discussing BCAs in pediatric CVR. A network meta-analysis (NMA) compared the effectiveness of different BCAs including tranexamic acid (TXA), aminocaproic acid (ACA), aprotinin, erythropoietin (EPO) and iron. RESULTS: Sixteen studies analyzing 1072 patients with a mean age of 15.6months and weight of 8.78kg were included. The most reported pathologies were sagittal (30.2%) and metopic (13.8%) craniosynostosis. TXA and ACA were independently associated with lower transfusion rates and volumes compared to placebo [ACA OR: 0.25, CI: 0.08-0.80; TXA OR: 0.17, CI: 0.07-0.42]. Combination therapy with TXA + EPO + Iron (OR: 0.004, CI: 0.002-0.10) or ACA + EPO (OR: 0.04, CI: 0.01-0.32) were associated with reduced transfusion rates. NMA ranking revealed TXA + EPO + Iron (SUCRA: 98.90%) and ACA + EPO (SUCRA: 75.41%) as the most effective treatments for reducing transfusion rates. While TXA was associated with significant reductions in blood loss compared to placebo (SMD: -1.26, CI: -1.97 to -0.56), ACA ranked highest for blood loss reduction (ACA SUCRA: 84.58% vs TXA SUCRA: 72.43%). Combination of TXA + EPO + Iron was associated with significantly reduced hospital length of stay (SMD: -1.00, CI: -1.71 to -0.29). No treatment significantly affected the duration of surgery and there were no reported treatment-associated thromboembolic events. CONCLUSIONS: Our meta-analysis reveals that TXA and ACA reduce RBC transfusion rates and volumes, with TXA + EPO + Iron and ACA + EPO being most effective. These findings highlight the superiority of combination BCA therapies and underscore the need for structured blood conservation protocols for pediatric CVR.

Fields of Study & Subjects

Blood transfusion and management Craniofacial Disorders and Treatments Trauma Hemostasis Coagulopathy Resuscitation

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
106–106
Publication date
26 March 2026
Language
EN